Codiak ($800mil market capitalisation), page-176

Well I guess you just lost your left nut, ouch how does that feel?

There is currently no technology that I know of that can quantify the contents of each individual exosome, so you'll have to rely on theory to answer this one. Exosomes encapsulate whatever the cell is producing at a particular point in time. They contain a variety of components such as membrane proteins, cytosolic proteins, messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), with the types and quantity of each component differing between each exosome.

For each particular stimulus a cell receives, it will increase the production of a certain type of these components (as well as other components unrelated to the stimulus e.g. housekeeping items) and these exosomes will encapsulate whatever is present in the cytosol, hence the fact that no two are alike. You can research it if you like, but those that are produced naturally by a cell are not homogenous, they are heterogenous. That is a fact! Feeling pretty sore right now are we? The FDA does not like heterogenous products, it goes against the purity test they need to approve a treatment. Secondly, how is EX1 going to identify the MOA when there are literally hundreds (or thousands) of components contained in the exosomes they give to patients? They will struggle to get the product approved.

This is why EX1 are also investigating engineered exosomes, which are basically drug transport vehicles. This company has massive risk associated with it. If they can pull it off then they would be another CSL in my opinion, but these products are so much more complex and carried more risk than what CSL produces, hence the reason why I think current shareholders are just funding scientific research. No offense intended, just facts.